Detailed recommendations for anesthesia and perioperative care of people with EDS should be used to improve safety.Surgery in people with EDS requires careful tissue handling and a longer immobilization afterward. Prognosis
The outcome for individuals with EDS depends on the specific type of EDS they have. Symptoms vary in severity, even in the same disorder, and the frequency of complications varies. Some people have negligible symptoms, while others are severely restricted in daily life. Extreme joint instability, chronic musculoskeletal pain, degenerative joint disease, frequent injuries, and spinal deformities may limit mobility. Severe spinal deformities may affect breathing. In the case of extreme joint instability, dislocations may result from simple tasks such as rolling over in bed or turning a doorknob. Secondary conditions such as autonomic dysfunction or cardiovascular problems, occurring in any type, can affect prognosis and quality of life. Severe mobility-related disability is seen more often in hEDS than in classical EDS or vascular EDS.Although all types of EDS are potentially life-threatening, most people have a normal lifespan. Those with blood vessel fragility, though, have a high risk of fatal complications, including spontaneous arterial rupture, which is the most common cause of sudden death. The median life expectancy in the population with vascular EDS is 48 years. Complications
Vascular
Pseudoaneurysm
Vascular lesions (nature is disputed) due to tears in the lining of the arteries or deterioration of congenitally thin and fragile tissue
Enlarged arteries

Gastrointestinal
A 50% risk of colonic perforation exists. Obstetric
Pregnancy increases the likelihood of uterine rupture. Maternal mortality is around 12%. Uterine hemorrhage can occur during the postpartum recovery.
Research
Mogamulizumab is being explored as a treatment for HTLV-1–Associated Myelopathy. An early Phase 1-2a study showed decreased in proviral loads, as well as inflammatory markers in the CSF. 79% of the patients showed reduction in spasticity and 32% showed decrease in motor disability. References
External links
"Mogamulizumab". Drug Information Portal. U.S. National Library of Medicine. "Mogamulizumab-kpkc". National Cancer Institute. 30 August 2018. "Mogamulizumab-kpkc". NCI Drug Dictionary. National Cancer Institute.